Document is current
Any future updates will be listed below
-
Authors
Larrauri, Carlos A.
Martinez-Martin, Nicole
Torous, John
- License Information
-
More Information
Article History
Received: 13 November 2025
Accepted: 25 May 2026
First Online: 2 June 2026
Competing interests
: C.A.L. has received payments for consulting services from Klick Health, Alkermes plc, K Health, Inc., Janssen Pharmaceuticals, Inc. (a Johnson & Johnson company), Discern Health (now part of Avalere Health), Neurocrine Biosciences, Inc., and Boehringer Ingelheim International GmbH; presentation and speaker fees from Merck & Co., Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., Intra-Cellular Therapies, Inc., Karuna Therapeutics, Inc. (a Bristol Myers Squibb Company), Cerevel Therapeutics Holdings, Inc., and Center for Patient Advocacy Leaders (Pfizer Inc.); travel support from Boehringer Ingelheim International GmbH; and medical writing support from Boehringer Ingelheim International GmbH and Teva Pharmaceutical Industries Ltd. C.A.L. is a member on a data safety monitoring board (DSMB) and clinical trial steering committee (CTSC) for Zucker Hillside Hospital and a Steering Committee co-chair at Accelerating Medicines Partnership Schizophrenia (AMP SCZ). N.M.-M. reports no financial or non-financial competing interests. J.T. serves on the editorial board of npj Digital Medicine . He is an adviser to Boehringer Ingelheim.
